NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of QIAGEN N.V. (: QGEN) to Thermo Fisher Scientific Inc. is fair to QIAGEN shareholders. On behalf of QIAGEN shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
If you are a QIAGEN shareholder and would like to discuss your legal rights and options, please visit QIAGEN Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
The QIAGEN merger investigation concerns whether QIAGEN and its directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for QIAGEN shareholders; (2) determine whether Thermo Fisher is underpaying for QIAGEN; and (3) disclose all material information necessary for QIAGEN shareholders to adequately assess and value the merger consideration.
If you are a QIAGEN shareholder and would like to discuss your legal rights and options, please visit https://halpersadeh.com/actions/qiagen-n-v-qgen-stock-merger-thermo-fisher/ or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
